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Despite two decades of studies documenting the in vitro blood-
forming potential of murine embryonic stem cells (ESCs), achieving
stable long-term blood engraftment of ESC-derived hematopoietic
stem cells in irradiated mice has proven difficult. We have exploited
the Cdx-Hox pathway, a genetic program important for blood
development, to enhance the differentiation of ESCs along the
hematopoietic lineage. Using an embryonic stem cell line engi-
neered with tetracycline-inducible Cdx4, we demonstrate that
ectopic Cdx4 expression promotes hematopoietic mesoderm spec-
ification, increases hematopoietic progenitor formation, and, to-
gether with HoxB4, enhances multilineage hematopoietic engraft-
ment of lethally irradiated adult mice. Clonal analysis of retroviral
integration sites confirms a common stem cell origin of lymphoid
and myeloid populations in engrafted primary and secondary mice.
These data document the cardinal stem cell features of self-
renewal and multilineage differentiation of ESC-derived hemato-
poietic stem cells.
Cdx4  clonal analysis  HoxB4
Transplantation of bone marrow (BM)-derived hematopoieticstem cells (HSCs) is the standard treatment for high-risk
leukemia and a range of genetic disorders of the blood. However,
a shortage of HLA-matched BMdonors and the inability to culture
and genetically repair BM-derived HSCs in vitro have limited more
widespread therapeutic applications (1). When generated by so-
matic cell nuclear transfer, pluripotent embryonic stem cells (ESCs)
provide a theoretically unlimited source of autologous hematopoi-
etic progenitors and an alternative strategy for treating leukemia
and genetic bone marrow disorders (2, 3). Although ESCs can
differentiate into all lineages of the blood system in vitro, efficient
production of functional HSCs that can reconstitute all hemato-
poietic lineages in vivo has proven difficult (4).
One approach to obtain definitive HSCs fromESCs is to enforce
expression of genes that stimulate hematopoiesis or enhance HSC
function. The homeodomain gene HoxB4 has been shown to
enhance competitive engraftment of murine BM-HSC and induce
proliferation of progenitors from human cord blood without in-
ducing leukemia, thereby making HoxB4 an excellent candidate
gene for our studies (5–11). Previously, we successfully engrafted
lethally irradiated mice with ESC-derived hematopoietic progeni-
tors engineered to ectopically express HoxB4. When introduced
into hematopoietic precursors dissected from the precirculation
murine yolk sac, HoxB4 promoted long-term multilineage engraft-
ment, suggesting that this homeodomain gene helped specify de-
finitive hematopoietic fate from primitive hematopoietic progeni-
tors (12). However, the extent and durability of lymphoid
engraftment from either ESCs or yolk sac populations was minimal
in these engrafted animals, possibly due to the inability to fully
pattern definitive HSCs from these embryonic populations.
Our understanding of how Hox genes promote hematopoietic
specification has been greatly advanced by insights into the role of
Cdx4, which along with Cdx1 and Cdx2 represent a family of
caudal-related homeobox-containing transcription factors that
specify posterior tissue fates and mediate anterior-posterior pat-
terning through modulation of hox gene expression (13–15). Cdx4
was shown to be necessary for blood formation in the zebrafish and
to promote hematopoietic colony formation when ectopically ex-
pressed in ESCs (16). Cdx4 null zebrafish have reduced expression
of hematopoietic genes, including SCL, Runx1, and GATA1,
whereas overexpression of Cdx4 induces ectopic blood formation
and altersHox gene expression patterns, including up-regulation of
HoxB4 (16). Cdx1 functions redundantly to promote blood forma-
tion in zebrafish (Alan Davidson, personal communication). Cdx2
is a translocation partner of TEL (ETV6) in human acute myeloid
leukemia (17), and overexpression of Cdx2 alone results in trans-
plantable acute myeloid leukemia in a mouse model (18). These
findings suggest that a genetic pathway involving cdx and hox genes
plays an essential role in blood formation and provide a central
mechanism for driving hematopoietic specification from ESCs.
In this study, we have explored the effect of Cdx4 expression on
hematopoiesis in the murine ESC system. Using a murine ESC line
with tetracycline-inducible Cdx4, we demonstrate that Cdx4 pro-
motes commitment to hematopoietic mesoderm, stimulates hema-
topoietic progenitor formation fromESCs, and promotes lymphoid
potential of ESC-derived HSCs. Using ESCs engineered to ectopi-
cally express both Cdx4 and HoxB4, we demonstrate radioprotec-
tion and robust and stable engraftment of hematopoietic lineages
in irradiated mice. Moreover, we apply proviral integration analysis
in fractionated myeloid and lymphoid lineages of primary and
secondary mice to document the clonal derivation of self-renewing,
multipotential HSCs from ESCs.
Methods
Cell Culture. ESCs were maintained and differentiated according to
published protocols in ref. 12. Doxycycline was added to the culture
medium from day 3 to day 4 at 0.1 gml and from day 4 to 6 at
0.5 gml to induce Cdx4 expression. Cells were harvested at day
6 by collagenase treatment. A total of 105 embryoid body (EB) cells
were plated onto semiconfluent OP9 cells in six-well dishes and
were infected with retroviral supernatants, produced in 293 cells by
Fugene (Roche) cotransfection of viral plasmid MSCV-HoxB4-
ires-GFP and packaging-defective helper plasmid, pCL-Eco. In-
fectedEB cells were cultured according to protocols in ref. 12. Blast
colony formingreplating assay and hematopoietic colony forma-
tion assay were performed as described in refs. 19 and 20.
RT-PCR Analysis and Quantitative Real-Time PCR. Cells were har-
vested in RNA Stat-60 (Tel-Test), and total RNA was isolated. All
RNA samples were treated with DNaseI and purified by RNeasy
MinElute kit (Qiagen). cDNAs were prepared according the man-
ufacturer’s instruction (Invitrogen). Real-time PCRwas performed
in triplicates with TaqMan reagent kits (Applied Biosystems) on an
ABI Prism 7700 Sequence Detector. GFP DNA levels were quan-
tified into arbitrary units by using the comparative CT method
(relative to the TDAG51 gene as an internal normalization control)
(21). For Fig. 1 E and F, test gene expression was normalized to
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-actin and relative expression levels were derived with the com-
parative CT method. For Fig. 2, probes labeled with FAM at the 5
end and TAMRA at the 3 end were purchased from Integrated
DNA Technologies. Multiplex reactions were performed with
rodent GAPDH VIC-labeled probeprimer sets as normalization
control (Applied Biosystems). Primerprobe sequences and PCR
conditions were listed in Tables 2 and 3, which are published as
supporting information on the PNAS web site.
Cell Transplantation. Six-week- to 3-month-old Rag2/c/ fe-
male mice were given two doses of 400 cGy -irradiation, separated
by 4 h and were injected via lateral tail vein with 2 106 cells in 400
l of IMDM2% IFS. Transplanted mice were maintained under
sterile conditions. Experiments were carried out with Institutional
Animal Care and Use Committee approval.
Spleen Colony Forming Assay. Six- to 10-week-old Rag2/c/
female mice were irradiated with a single dose of 900 cGy -irra-
diation and 105 whole BM or 106 ESC-derived hematopoietic
progenitor cells were administered retroorbitally in 200 l of PBS.
An equal number of mice were irradiated and injected with PBS to
control for host-derived spleen colonies. Mice were killed on
different time points, and their spleens were fixed in Bouin’s buffer
and scored for the colony-forming units of the spleen (CFU-S).
FACS Analysis. Peripheral blood leukocytes, splenocytes, and bone
marrow cells were treated with red cell lysis buffer (Sigma).
Antibodies were purchased from Pharmingen BD Biosciences.
Propidium iodide was added to exclude dead cells. Gr1, B220, or
Fig. 2. Hox gene expression profile in hematopoietic populations isolated
from EBs by flow cytometry, determined by quantitative real-time RT-PCR
analysis. (Upper) Flk1 cells from day 4 EBs with (dox) or without (dox)
Cdx4 induction from days 2 to 4 of EB differentiation. (Lower) CD41 cells from
day 6 EBs with (dox) or without (dox) Cdx4 induction from days 3 to 6 of
EB differentiation.
Fig. 1. Characterization of ESC-derived hemangioblast and hematopoietic progenitors from an inducible Cdx4 cell line. (A) Quantification of blast
colony-forming cells (BL-CFCs). A total of 3  104 EB cells harvested on day 3.2 of differentiation from an inducible Cdx4 cell line were plated in blast-colony
forming media in the absence or presence of doxycycline (dox), and colonies were counted 4 days after plating. A photograph of a representative blast colony
is shown (Inset). (B) Methylcellulose colony-forming potential of day 6 EB-derived cells plated in methylcellulose containing cytokines (M3434). Colonies were
counted from day 5 to 10 after plating. EryPEryD, primitivedefinitive erythroid; GEMM, granulocyte, erythroid, macrophage, megakaryocyte multilineage; GM,
granulocyte macrophage; Mac, macrophage; Mast, mast cell. (C) Flow cytometric analysis of c-kit and CD41 on day 6 EBs. (D) Inducible Cdx4 ESC were treated
with doxycycline from days 3 to 6 of EB formation and cultured on OP9 cells in the absence or presence of doxycycline. Fold increase of cell number on day 18
of OP9 culture was calculated relative to the initial cell number. (E) Relative expression levels of fetal (-H1) and adult hemoglobin (-major) before and after
OP9 expansion by real-time RT-PCR analysis. (F) Relative expression levels of genes specific to different hematopoietic and lymphoid development pathways in
Cdx4-induced or HoxB4-induced ESC-derived hematopoietic progenitors 15 days after OP9 expansion.
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CD3 cells were isolated either by FACS sorting or by positive
selection with magnetic streptavidin-conjugated Dynabeads M280
(Dynal Biotech). The purity of sorted cells was verified by post-
sorting FACS analysis.
Genomic DNA Isolation and Southern Hybridization.GFP andHoxB4
probes were obtained separately by purification of an NcoIClaI
digested fragment from MSCV-ires-GFP and an EcoRIXhoI
fragment from MSCV-HoxB4-ires-GFP with a MinElu gel purifi-
cation kit (Qiagen). Probes were labeled and Southern hybridiza-
tionwas performed according to standard protocols. Band intensity
was measured by IMAGEQUANT.
Results
Cdx4 Expression Enhances Hemangioblast Formation. The first he-
matopoietic cell to be detected in EBs is the hemangioblast, a
bipotential precursor of hematopoietic and endothelial lineages (19,
22). Hemangioblasts are detected on days 3 and 4 of in vitro
differentiation of ESCs into EBs, the time interval when Cdx4
expression is highest (16). Therefore, we examined whether en-
forced expression ofCdx4 could promote hemangioblast formation.
To achieve conditional gene induction of Cdx4, a mouse Cdx4
cDNAwas cloned into the Ainv15 ESC line such that its expression
is controlled by a tetracycline responsive promoter element (Fig.
6A, which is published as supporting information on the PNAS web
site; 12). RT-PCRconfirmed the induction ofCdx4 after incubation
of the cells for 24 hwith tetracycline analogue doxycycline (Fig. 6B).
Doxycycline was added to the EB differentiation media from day
2 to 3.2 (to allow maximal gene induction at 24 h, ref. 23) before
blast colony assay in methylcellulose. Additionally, doxycycline was
added to some methylcellulose cultures. Induction of Cdx4 expres-
sion during EB development stimulated the formation of blast
colonies, and the yield was further increased when Cdx4 was
continuously induced during methylcellulose culture (Fig. 1A).
Individual blast colonies were picked, replated, and shown to
generate both endothelial and hematopoietic progeny (Table 4 and
Fig. 7, which are published as supporting information on the PNAS
web site). Cdx4 induction not only enhances formation of the
hemangioblast, but appears to favor its differentiation toward
hematopoietic fates.
Cdx4 Promotes both Primitive and Definitive Hematopoiesis in Vitro.
To determine whether induction of Cdx4 over a prolonged time
interval might promote hematopoietic progenitor development in
EBs, we incubated EBs with doxycycline from days 3 to 6 of
differentiation and observed increased numbers of primitive ery-
throid and multipotential hematopoietic colonies (Fig. 1B). Cells
expressing CD41 and c-kit, markers on early hematopoietic pro-
genitors in both embryos and EBs (24–26), were also increased in
day 6 EBs exposed to doxycycline (Fig. 1C), suggesting that Cdx4
promotes hematopoietic colony formation by enhancing the spec-
ification, proliferation, or survival of clonogenic hematopoietic
progenitors. Consistent with this finding, we demonstrated by using
real-time RT-PCR that the expression level of hematopoietic-
specific genes was elevated 2- to 3-fold in whole EBs after Cdx4
activation between days 3 and 6 (Fig. 8, which is published as
supporting information on the PNAS web site), suggesting that the
enhanced gene expression byCdx4 reflects an increased percentage
of hematopoietic cells in whole EBs.Of the genes we assayed,-H1,
Tie2, LMO2, Scl, and GATA1 reflect both early hematopoietic
development and definitive lineage differentiation, whereas -
major, c-myb, and AML1 are markers of definitive hematopoiesis
(reviewed in ref. 27). Elevated expression of these genes suggests
that Cdx4 activation promotes both primitive and definitive hema-
topoietic progenitor formation from differentiated ESCs.
OP9 is a stromal cell line derived fromM-CSFdeficientmice that
supports the growth of hematopoietic progenitors (28). When EBs
are dissociated and plated ontoOP9, we typically observe only scant
outgrowth of hematopoietic populations. However, induction of
Cdx4 enabledEB-derived hematopoietic progenitors to expand and
undergo multilineage differentiation on OP9, as reflected by total
cell counts (Fig. 1D) and flow cytometry with hematopoietic
markers (Table 1). Compared to the gene expression profile of
hematopoietic populations from day 6 EBs, expression of -H1
embryonic globin was significantly reduced, whereas the expression
of -major, the adult-type globin, was markedly elevated after
coculture on OP9 stroma, indicating that Cdx4 promotes matura-
tion of definitive erythroid lineages (Fig. 1E).
Induction ofHoxB4 expression in EB-derived cells also promotes
expansion of hematopoietic progenitors on OP9 stroma (12).
Therefore, we compared the surface antigen and gene expression
profile of OP9 cocultured cells expanded by either Cdx4 orHoxB4.
Of the lineage-specific surface antigens we assayed, cultures stim-
ulated by Cdx4 show a higher percentage of B220 cells, suggestive
of enhanced lymphoid differentiation potential (Table 1). Expres-
sion of genes linked to B cell development was likewise increased
in Cdx4-induced OP9 cocultured cells (Fig. 1F). By surface antigen
profile, 76% of Cdx4-expanded cells displayed surface antigen
features comparable to definitive hematopoietic progenitors de-
rived from the aorta-gonad-mesonephros region of the embryo,
namely coexpression of CD41CD31CD34c-kit (29–31).
They likewise appear to acquire CD45 expression during matura-
tion in vitro. By contrast, cells stimulated to proliferate on OP9 by
HoxB4 expression had lower levels of CD34 and CD45. CD45 is a
pan-hematopoietic marker that is developmentally regulated, ap-
pearing on mature hematopoietic populations after activation of
CD41 in both the embryo and EBs (24, 25). Our observation of a
higher percentage of CD45 cells in our Cdx4-expanded EB-
derived populations suggests that Cdx4 and culture on OP9 stroma
promotes the switch from primitive to definitive hematopoiesis
more efficiently than HoxB4. CD34 is developmentally and func-
tionally regulated, and its expression is influenced by the activation
state of stem cells (32, 33). Higher expression of CD34 in
Cdx4-expanded cells suggests that these cells are in an actively
cycling state, consistent with the rapid proliferation of the cultures.
Cdx4 Induction Modulates Hox Gene Expression in Hematopoietic
Cells. Genetic and molecular biological studies in Drosophila, ze-
brafish, and mouse have established that the Caudal-related family
of homeodomain transcription factors regulates Hox gene expres-
sion patterns (reviewed in ref. 13). To explore the Hox gene
expression profiles that result from Cdx4 induction during hema-
topoietic commitment in EBs, we performed real-time RT-PCR
Table 1. Surface antigen expression of ESC-derived cells growing
on OP9 for 23 days
Lineage Surface marker icdx4dox ihoxB4dox
Myeloid Gr-1 5.57 6.60
Mac-1 52.17 28.31
Erythroid Ter119 0.62 0.36
Lymphoid CD4 0.10 0
CD8 0 0
B220 7.21 0.70
ProgenitorMeg HSC CD41 85.94 89.94
Scal 43.63 16.16
c-kit 96.70 75.70
c-kitScal 42.10 12.10
HSCEndothelial CD31 98.36 85.06
CD34 92.22 10.25
CD3134 91.93 11.20
Flk-1 0.31 0.26
VE-Cadherin 71.73 51.23
Endoglin 68.83 53.43
Pan-hematopoietic CD45 85.32 50.40
CD313445 83.98 5.74
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analysis on the expression ofHoxA, B, and C cluster genes in Flk1
day 4 EB cells and CD41 day 6 EB cells. Cdx4 induction resulted
in enhanced expression of posteriorHox genes (A6,A7,A9,A10,B9,
and C6) in these hematopoietic populations (Fig. 2). Comparable
induction was not observed in the nonhematopoietic Flk1 fraction
of cells (data not shown). These data suggest that Cdx4 promotes
blood formation by influencing Hox gene patterning during hema-
topoietic mesoderm commitment.
Cdx4 Enables Engraftment of ES-Derived Hematopoietic Progenitors.
Wenext exploredwhetherCdx4 enables engraftment of ES-derived
hematopoietic progenitors in lethally irradiated mice (schema in
Fig. 9A, which is published as supporting information on the PNAS
web site). Contrary to our expectations, hematopoietic populations
derived from Cdx4-induced EBs protected only a minority of mice
(8 of 30) from radiation-induced bone marrow aplasia. Donor
chimerism in surviving mice was low (average 1%, Fig. 9B),
suggesting that the transplanted population contained only small
numbers of definitive HSCs or was comprised of progenitors with
limited self-renewal potential.We noted thatCdx4 induction inEBs
increased HoxB4 expression only 2-fold and that OP9 cocultured
cells expanded by HoxB4 induction (or retroviral transduction of
HoxB4) expressed significantly moreHoxB4 than cells expanded by
Cdx4 (Fig. 2 and data not shown). Theweak enhancement ofHoxB4
expression by Cdx4 appears inadequate to maintain or expand
transplantable HSCs on OP9 stromal cultures. Given thatHoxB4 is
a major factor in the self-renewal and expansion of ESC-derived
HSCs, we examined whether combining the hematopoietic speci-
fication ability of Cdx4 with the self-renewal potential of HoxB4
could improve engraftment of hematopoietic populations derived
from differentiated ESCs. EBs were formed from the conditional
Cdx4 cell line. Some cultures were left uninduced, whereas others
were induced by doxycycline during days 3 to 6 of EB development.
At day 6, EB cells from both sets of cultures were transduced with
a retroviral vector expressing HoxB4 linked via internal ribosomal
entry site (ires) to green fluorescent protein (GFP) and subse-
quently cultured on OP9 stromal cells for 10–14 days (under our
present conditions, OP9 coculture appears to be a necessary step
before transplantation; see also ref. 12). Cultured cells were then
injected intravenously into lethally irradiated lymphocyteNK cell-
deficient Rag2/c/ mice (34).
A cohort of animals injected with 106Cdx4-HoxB4modified cells
were killed at different time intervals and examined for evidence of
short-term hematopoietic chimerism in the bone marrow, spleen,
and peripheral blood. Within 8–12 days, animals developed high
levels of GFP cells in all hematopoietic tissues tested and showed
characteristic splenic hematopoietic colonies (CFU-S, Fig. 3). Al-
though not the equivalent of the long-term HSC (35), the CFU-S
reflects a primitive multipotent myeloid progenitor that previously
has not been demonstrated reliably in animals engrafted fromESCs
differentiated in vitro. The frequency of CFU-S detectable in
stromal cocultures (14.7 3 in 106 cells) is10-fold less than whole
bone marrow (data not shown). These data suggest that EB cells
expanded on OP9 stromal cocultures produce hematopoietic pro-
genitors that support rapid engraftment after radiation-induced
marrow aplasia.
In data from three independent transplantation experiments
with cells genetically modified by eitherHoxB4 alone, or both Cdx4
and HoxB4, survival due to the radioprotective effect of trans-
planted cells was close to 100% at 8 weeks (12 of 13 for HoxB4; 18
of 18 for Cdx4HoxB4). Flow cytometric monitoring of GFP cells
in the peripheral blood of transplanted animals showed high-level
donor chimerism that was stable over at least 6 months (Fig. 4A).
Moreover, myeloid, lymphoid, and erythroid lineages were recon-
stituted in the peripheral blood, spleen, lymph nodes, bonemarrow,
and thymus of engrafted mice (Fig. 4B; see also Fig. 10 A–C, which
is published as supporting information on the PNAS web site; see
also ref. 36). Interestingly, when compared with mice transplanted
with cells treated with HoxB4 alone, mice engrafted with Cdx4
HoxB4-treated cells consistently showed a higher degree of lym-
phoid reconstitution (Fig. 4B and 10 A–C), a result that correlated
with the enhanced percentage of B220 cell formation in OP9
cultures (Table 1). Bone marrow from primary animals engrafted
with Cdx4HoxB4-expressing cells successfully reconstituted mul-
tiple lineages of hematopoietic cells when transplanted into lethally
Fig. 3. Donor cell chimerism and CFU-S formation in mice engrafted with
cdx4hoxB4-modified cells. Mice were killed from days 6 to 12 and their
spleens analyzed for CFU-S formation; the picture (Lower Right) shows a
representative d12 spleen after fixation.
Fig. 4. Donor cell chimerism and multilineage engraftment in irradiated primary and secondary mice. (A) Donor chimerism (%GFP) in peripheral blood of mice
engrafted with HoxB4 or Cdx4HoxB4 modified hematopoietic populations differentiated from ESCs 22 weeks after transplantation. (B) Flow cytometry
analysis of peripheral blood cells expressing either myeloid antigens (Gr-1, M) or lymphoid antigens (CD3B220, L). Number of mice analyzed at each time point
is indicated. (C) Donor chimerism in peripheral blood of secondary animals. Bone marrow (BM) from primary recipients engrafted at least 12 weeks was
transplanted into secondary recipients. (D) Myeloid-lymphoid reconstitution of splenocytes from secondary animals. Error bars represent standard deviation. 1ry,
primary; 2ry, secondary.
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irradiated secondary mice (Fig. 4 C and D and 10 D and E).
Moreover, the thymus from both primary and secondary engrafted
animals was reconstituted with CD4CD8 cells for 4 months
after transplantation (Fig. 10 B and E), indicating stable and
long-term engraftment of the lymphoid lineage. Taken together,
the existence of CD4CD8 double-positive cells in the thymus of
both primary and secondary engrafted mice and the detection of
the expected blood lineages in the peripheral blood, spleen, lymph
nodes, bone marrow, and thymus suggested stable hematopoietic
reconstitution with self-renewing, multipotential HSCs.
Clonal Analysis of Engrafted Mice. Clonal analysis of marked donor
cells is the accepted standard for documenting the BM-HSC (37,
38), and the introduction of HoxB4 via retrovirus into the ESC-
derived hematopoietic populations allowed us to use proviral
integration sites as unique geneticmarkers (Fig. 5A; see also Fig. 11,
which is published as supporting information on the PNAS web
site). Genomic DNA was isolated from either spleen or bone
marrow cells of primary and secondary mice. In some cases,
genomic DNA was extracted from populations of Gr-1 myeloid
cells and B220 and CD3 lymphoid cells that were purified by
antibody-conjugated magnetic beads or flow-cytometric sorting to
99% homogeneity. Isolated DNA was digested with EcoRI and
NcoI and analyzed by Southern hybridization with probes that
reflected either the unique proviral integration site (GFP) or the
fragment of the HoxB4 cDNA common to all proviruses (Fig. 5A),
as well as endogenous HoxB4, which served as an internal DNA
loading control. In essentially all samples tested, we detected
multiple comigrating fragments (bands), representing shared pro-
viral integration sites, in cells from spleen and bone marrow, and
from fractionated myeloid and lymphoid cell populations from
primary and secondary mice (Fig. 5 B and C). Importantly, several
comigrating fragments were seen in paired primary and secondary
mice after long-term engraftment (17 weeks), indicating that
multiple clones carried extensive self-renewal capacity (Fig. 5B and
C). Moreover, by comparing the hybridization intensity of the
endogenous and proviralHoxB4 fragments, we calculated thatmost
tissues harbored one to three proviral copies per cell and showed
engraftment with 3–15 prominent clones (Fig. 5B andC). Although
most tissues harbor comigrating bands, not all clones are repre-
sented among all tissues in paired samples. Some fragments were
seen only in primary recipients (Fig. 5B, #), others were unique to
secondary engrafted animals (Fig. 5B, *), and some were seen
predominantly in one lineage (Fig. 5 B and C, ˆ). Such clonal
extinction, clonal succession, and lineage restriction is an expected
feature of HSC dynamics (39).
Discussion
In the present study, we demonstrate that Cdx4 expression can
stimulate hematopoietic development in differentiating cultures of
ESCs, as documented by increased numbers of hemangioblasts and
multipotential hematopoietic progenitors within EBs, expansion of
definitive hematopoietic and lymphoid progenitors in stromal
co-cultures, and improved lymphoid engraftment of irradiated
recipient mice. We also employ clonal analysis of retroviral inte-
gration sites in hematopoietic populations of engrafted mice to
demonstrate our derivation of self-renewing, multipotential HSCs
from ESCs. Thus, our culture conditions enable the directed
differentiation of ESCs into hematopoietic progenitors with the
cardinal features of definitive HSCs.
Although the physiological function of Cdx4 during mamma-
lian embryonic hematopoiesis is not yet clearly understood,
Caudal-related family members act as master regulators of Hox
genes in anterior-posterior pattering (reviewed in ref. 13), and
Cdx4 induces several Hox genes that are known to play roles in
both normal and leukemic hematopoiesis (HoxA6, A7, A9, A10,
Fig. 5. Clonal analysis of hematopoietic populations of mice engrafted with ESC-derived HSCs, as determined by Southern hybridization analysis of retroviral
integration sites. (A) Structure of the retroviral vector MSCV-HoxB4-ires-GFP. Probes used in Southern hybridization analysis are indicated. (B Left) Southern
analysis of fractionated myeloid and lymphoid populations from primary (1ry) and unrelated secondary (2ry) engrafted mice, showing multiple comigrating
fragments. (B Right) Bone marrow and spleen cells from two primary engrafted animals and comparable tissue from the corresponding secondary animals,
showing comigrating fragments. (C) Southern analysis of hematopoietic tissues from one primary and two corresponding secondary recipients engrafted with
ESC-HSCs: spleen (S), BM (B), Gr1 BM cells (BG), Gr1 splenocytes (SG), and CD3 or B220 splenic lymphocytes (SL). MyeLym represents the ratio of Gr-1
cells to CD3 and B220 populations in corresponding sample, as determined by flow cytometry. Relative DNA level was calculated by comparing endogenous
HoxB4 (endog) with control (DNA isolated from Ainv15 ES cells). Proviral copy number was calculated by comparing the level of proviral HoxB4 (Rv-HoxB4) with
endogenous HoxB4 level. Samples reflect Cdx4HoxB4-engrafted cells, except the third and fourth lanes in B Left, which represent HoxB4-treated cells. #,
fragments detected only in primary recipients; *, fragments unique to secondary engrafted animals; ˆ, fragments detected predominantly in one lineage.
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HoxB4, B8, and B9; refs. 40–42).Cdx4 overexpression can rescue
blood progenitor formation in ESCs that are deficient in Mll, a
Hox gene regulator involved in definitive hematopoiesis (26, 43,
44). Cluster C Hox genes such as C6, whose expression is also
enhanced by Cdx4 activation, are particularly linked to lymphoid
development (45–47). Given the role of Cdx genes in patterning
of posterior tissues during embryogenesis, we conclude thatCdx4
is acting to enhance mesodermal commitment to hematopoietic
fates through modulation of theHox code. No significant defects
in hematopoiesis were observed in Cdx1 andor Cdx2 knockout
mice, with the exception that yolk sac circulation is abnormal in
Cdx2-deficient embryos (14, 15). However, given the reports of
Cdx2 involvement in human and murine leukemogenesis (17,
18), it is likely that there are overlapping and, perhaps, redun-
dant roles of the Cdx genes in hematopoiesis.
Previously, we showed that expression of HoxB4 in differentiat-
ing ESCs or primitive yolk sac progenitors enabled engraftment of
irradiated mice, but the recipient animals showed only low levels of
lymphoid reconstitution (12). Despite initial reports that retroviral
transduction of bonemarrowwithHoxB4 producedHSCexpansion
and enhanced competitive engraftment without distortion of he-
matopoietic differentiation (5–7), several groups have now ob-
served alterations in the lympho-myeloid differentiation program
(9, 11, 49). We conclude that HoxB4 can compromise lymphoid
engraftment, because the predominant lymphocyte populations in
our engrafted animals lack GFP expression, which we have shown
correlates with the transcriptional silencing of the HoxB4 provirus
(see Fig. 12, which is published as supporting information on the
PNASweb site). Current efforts are underway to deriveHSCs from
ESCs without ectopic HoxB4 gene expression, and evidence exists
from one study that HoxB4 is dispensable for generating hemato-
poiesis from human (48).
The self-renewing, multipotential nature of the HSC was dem-
onstrated definitively in the mid-1980s in experiments that used
retroviruses as unique genetic markers to traceHSC fates following
bone marrow transplantation (37, 38). The demonstration that
highly purified lymphoid and myeloid blood cells in engrafted mice
showed common sites of proviral integration established that
multiple blood lineages derived from single precursor cells. Some
of these clones were detected again in the hematopoietic tissue of
secondary recipient mice (38, 39). The evidence that single clones
can reconstitute the lympho-myeloid system of both primary and
secondary recipients established the paradigmatic definition of
stem cells as self-renewingmultipotential progenitors. In this study,
we applied classical Southern hybridization analysis of proviral
integration sites in engrafted blood lineages of primary and sec-
ondary mice to demonstrate the clonal derivation of HSCs from
murine ESCs. Long-term reconstitution of primary and secondary
mice with common clones demonstrates self-renewal, whereas
evidence that myeloid and lymphoid cells derive from common
clones demonstrates multilineage differentiation potential. Taken
together, our data validate the classical definition of a self-
renewing, multilineage hematopoietic stem cell and indicate the
successful derivation of long-term HSCs from ESCs in vitro. The
application of similar principles to the derivation of HSCs from
human ESCs, coupled to methods to generate genetically matched
ESCs by nuclear transfer, provides an important theoretical foun-
dation for combined cell and gene therapy for the treatment of
genetic and malignant disorders of the blood (3).
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